Radiopharm Theranostics Limited (ASX: RAD)
Health Care · Biotechnology · AU
AU$0.01
-8.33% today · -57.7% 1Y
Radiopharm Theranostics Limited (ASX: RAD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $33.82M and employs 14 people.
Over the last twelve months the share price has lost 57.7%, trading between 0.01 and 0.04.
Tweenvest scores Radiopharm Theranostics Limited across four factors: quality 27/100, value 50/100. Its strongest factor is value.
RAD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.82M
- Revenue (TTM)
- $10.86M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.77
- 52-week high
- AU$0.04
- 52-week low
- AU$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 4.34B
- Employees
- 14
- Next earnings
- —
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
- Founded
- 2021
- Listed since
- Nov 25, 2021
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.85 | +0.34% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.74 | +0.09% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.56 | +0.30% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €880.20 | -2.42% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.47 | -1.10% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.